000			02359 a2200745 4500
005			20250517103718.0
264		0	_c20170605
008			201706s 0 0 eng d
022			_a1473-1150
024	7		_a10.1038/tpj.2016.51 _2doi
040			_aNLM _beng _cNLM
100	1		_aMusolino, A
245	0	0	_aImmunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. _h[electronic resource]
260			_bThe pharmacogenomics journal _c10 2016
300			_a472-7 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBiomarkers, Tumor _xanalysis
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aClinical Trials, Phase II as Topic
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aGene Frequency
650	0	4	_aGenotype
650	0	4	_aHumans
650	0	4	_aLapatinib
650	0	4	_aMastectomy
650	0	4	_aMiddle Aged
650	0	4	_aNeoadjuvant Therapy
650	0	4	_aPharmacogenetics
650	0	4	_aPharmacogenomic Testing
650	0	4	_aPharmacogenomic Variants
650	0	4	_aPhenotype
650	0	4	_aPolymorphism, Single Nucleotide
650	0	4	_aProtein Kinase Inhibitors _xadverse effects
650	0	4	_aQuinazolines _xadverse effects
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aReceptor, ErbB-2 _xanalysis
650	0	4	_aReceptors, IgG _xgenetics
650	0	4	_aRetrospective Studies
650	0	4	_aTime Factors
650	0	4	_aTrastuzumab _xadverse effects
650	0	4	_aTreatment Outcome
700	1		_aNaldi, N
700	1		_aDieci, M V
700	1		_aZanoni, D
700	1		_aRimanti, A
700	1		_aBoggiani, D
700	1		_aSgargi, P
700	1		_aGenerali, D G
700	1		_aPiacentini, F
700	1		_aAmbroggi, M
700	1		_aCagossi, K
700	1		_aGianni, L
700	1		_aSarti, S
700	1		_aBisagni, G
700	1		_aArdizzoni, A
700	1		_aConte, P F
700	1		_aGuarneri, V
773	0		_tThe pharmacogenomics journal _gvol. 16 _gno. 5 _gp. 472-7
856	4	0	_uhttps://doi.org/10.1038/tpj.2016.51 _zAvailable from publisher's website
999			_c26191409 _d26191409